Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and ...

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...

Sinema has backed a bill advancing in the Arizona legislature that would include a $5 million grant to a neurological ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a ...

Midi Health, the virtual care company best known for providing hormone therapy for women in menopause, is expanding to ...

The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal ...

Oric Pharmaceuticals raises $125M for Phase 3 prostate cancer drug ORIC-944 after positive early results, with study planned ...

EDO51 for Duchenne muscular dystrophy after Phase 2 trial failure, abandons three preclinical programs, and pivots to focus ...

Eisai and Merck succeeded in stopping Shilpa Medicare Ltd. from launching a generic version of Lenvima for at least another ...